Stronger bones. Healthier joints. Same daily protein.
Structural nutrition that fits into your daily routine — engineered for the proteins your body stops making on its own.
The problem
Your body is losing the one protein it can't live without.
1–1.5%
collagen lost per year after 30
Collagen holds your bones, joints, and skin together. After 30, you lose it every year. By 50, a third of it is gone — and no regular protein product puts it back.
We built Collafyx because what should exist — didn't.
Why Collafyx
One formula for the body’s structure.
Most products sell protein or collagen separately. Collafyx brings muscle, joint, bone, and beauty-from-within support into one clean structural matrix.
Bone Support
Vitamin D3 and calcium for everyday structural strength.
Joint Support
ESM with collagen Type X, hyaluronic acid, glucosamine, and chondroitin.
Beauty Support
Collagen Types I and V for skin, hair, nails, and active aging.
Product lineup
Seven formats. One structural matrix.
Protein Bars
The ultimate structural superfood
Wafers
Crisp protein convenience
Chips
Savory structural snacking
Electrolytes
Hydration plus protein
Protein Powders
Daily recovery ritual
Capsules
Focused nutraceutical dosing
Gummies
Easy daily habit
Built to scale
Formula, manufacturing, and distribution in one system.
Collafyx Formula
A proprietary structural matrix built with eggshell membrane, egg protein, D3, calcium, and clinically meaningful dosing.
3P Manufacturing
Cold-process, export-grade production with FSSAI, WHO-GMP, allergen control, and clean label discipline.
Product Platform
One core ingredient system designed for wafers, chips, hydration, powders, capsules, and gummies.
Global reach
Formulated here. Shipped anywhere in the world.
Avestra ships export-grade Collafyx products to partners across MENA, GCC, Europe, USA, and beyond — clean label, third-party tested, and ready for any market.
- Export-ready, WHO-GMP compliant production
- Third-party tested — clean label guaranteed
- Worldwide distribution & 3P contract manufacturing
The investment thesis
Why Avestra. Why now.
The Gap
India's nutraceutical market is accelerating toward ₹15,000 Cr. — yet no brand has solved structural nutrition. Products sell either protein or collagen. Never both. The shelf is empty. We intend to own it.
The White Space
Muscle. Joint. Bone. Beauty-from-within. Collafyx is the first clinical-grade formula to address all four simultaneously — in a cold-processed format that actually preserves bioactivity. No competitor comes close.
The Science
300–500mg clinical ESM dose. Collagen Types I, V & X naturally occurring. PDCAAS of 1.0. Hyaluronic acid, glucosamine, chondroitin, D3, and calcium — synergistic, not additive. Results felt in 7–10 days, not months.
The Model
D2C-first with 55%+ gross margins. Export-grade from day one. WHO-GMP certified manufacturing, allergen-controlled, third-party tested. MENA, GCC, Europe, and USA are the next chapters. The infrastructure is already built.
Our story
"We didn't set out to build a supplement brand. We set out to fix what was broken in nutrition science."
Fifteen months ago, four people walked into the same problem from four different directions. One of them — a founder with years spent inside the food industry — kept asking the same question at every trade show, every launch event, every investor room: why does true structural nutrition still not exist? Protein bars for muscle. Collagen shots for skin. But nothing — not a single product on any shelf anywhere — had brought the complete picture together in a format people would actually use every day.
Then came the others. A formulation expert who had spent a decade in clinical nutrition and knew the science of Hydrolyzed Eggshell Membrane better than almost anyone in the country. An operations mind who had scaled cold-chain manufacturing for some of India's most exacting food brands. And a strategist who understood that the best product in the world means nothing without the right story and the right distribution.
They didn't meet at an accelerator. They didn't get introduced by a venture firm. They found each other the way the best partnerships always do — through a shared obsession. That the supplement industry had been misleading people for years. Not maliciously, but lazily. Proprietary blends masking sub-therapeutic dosing. Products with 50mg of an active ingredient — a rounding error dressed up as a scientific breakthrough.
They started Avestra to fix that. What followed was fifteen months of formula work, failed cold-process batches, FSSAI filings, WHO-GMP facility audits, and ingredient sourcing across three countries. Fifteen months of refusing shortcuts. Of insisting on 300–500mg clinical dosing when 50mg was cheaper. Of choosing cold-processing when baked was easier. Of building a product that had to work — because their reputations were on it, even if the world didn't know their names yet.
The result is Collafyx. Avestra is the company built to carry it.